SALIX PHARMACEUTICALS LTD
SC 13G, 2000-02-15
PHARMACEUTICAL PREPARATIONS
Previous: MYERS JAMES M RESEARCH INC/NC, 13F-HR, 2000-02-15
Next: SALIX PHARMACEUTICALS LTD, SC 13G/A, 2000-02-15



                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                  SCHEDULE 13G

                    UNDER THE SECURITIES EXCHANGE ACT OF 1934

                               (AMENDMENT NO. _)*

                           Salix Pharmaceuticals, Ltd.
                           ---------------------------
                                (Name of Issuer)

                                  Common Stock
                                  ------------
                         (Title of Class of Securities)


                                   794906 3 05
                            ------------------------
                                 (CUSIP Numbers)

                                February 4, 2000
                   -------------------------------------------------
             (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:

         [ ] Rule 13d-1(b)
         [X] Rule 13d-1(c)
         [ ] Rule 13d-1(d)
- ------------------------
         *The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would
alter disclosures provided in a prior cover page.

         The information required on the remainder of this cover page shall not
be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
<PAGE>
____________________________________________________________
1.       Name of Reporting Person
         I.R.S. Identification No. of Above Person

         Robert P. Ruscher
____________________________________________________________
2.       Check the Appropriate Box if a Member of a Group
           (See Instructions)
                                                                       (a) ____
            Not Applicable                                             (b) ____

____________________________________________________________
3.       SEC Use Only

____________________________________________________________
4.       Citizenship or Place of Organization

            United States
____________________________________________________________
                           5.       Sole Voting Power

Number of                                   877,811
Shares                     ________________________________________
Beneficially               6.       Shared Voting Power
Owned By
Each Reporting
Person                     ________________________________________
                           7.       Sole Dispositive Power

                                            877,811
                           ________________________________________
                           8.       Shared Dispositive Power

____________________________________________________________
9.       Aggregate Amount Beneficially Owned by Each
           Reporting Person

                  877,811
____________________________________________________________
<PAGE>
10.      Check if the Aggregate Amount in Row (9) Excludes
           Certain Shares (See Instructions)

                  /   /
____________________________________________________________


11.      Percent of Class Represented by Amount in Row (9)

                  8.03%
____________________________________________________________
12.      Type of Reporting Person (See Instructions)

         IN
____________________________________________________________
<PAGE>
ITEM 1(A)   NAME OF ISSUER

            Salix Pharmaceuticals, Ltd.

ITEM 1(B)   ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES

            3600 W. Bayshore Road, Suite 205, Palo Alto, CA 94303

ITEM 2(A)   NAME OF PERSON FILING

            Robert P. Ruscher

ITEM 2(B)   ADDRESS OF PRINCIPAL BUSINESS OFFICE, OR, IF NONE, RESIDENCE

            3600 W. Bayshore Road, Suite 205, Palo Alto, CA 94303


ITEM 2(C)   CITIZENSHIP

            United States


ITEM 2(D)   TITLE OF CLASS OF SECURITIES

            Common Stock


ITEM 2(E)   CUSIP NUMBER
            794906 3 05


ITEM 3.  FILING PURSUANT TO RULES 13D-1(B) OR 13D-2(B)

            Not Applicable

ITEM 4.  OWNERSHIP

            (a)      Amount beneficially owned: At February 4, 2000, Mr.
                     Ruscher beneficially owned an aggregate of 877,811
                     shares of the Issuer's common stock which includes
                     options to purchase 225,308 shares of the Issuer's
                     common stock that were exercisable within 60 days of
                     February 4, 2000.

            (b)      Percent of class:
<PAGE>
                     8.03%


       (c) Number of shares as to which such person has:

           (i)   Sole power to vote or to direct the vote:  877,811
           (ii)  Shared power to vote or to direct the vote:
           (iii) Sole power to dispose or to direct the disposition of:  877,811
           (iv)  Shared power to dispose or to direct the disposition of:


ITEM 5.  OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

                 Not Applicable

ITEM 6.  OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

                 Not Applicable

ITEM 7.  IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE
                  SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY

                 Not Applicable

ITEM 8.  IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP

                 Not Applicable

ITEM 9.  NOTICE OF DISSOLUTION OF GROUP

                 Not Applicable

ITEM 10. CERTIFICATION

                  The following certification shall be included if the statement
is filed pursuant to Rule 13d-1(c):

         By signing below I certify that, to the best of my knowledge and
belief, the securities referred to above were not acquired and are not held for
the purpose of or with the effect of changing or influencing the control of the
issuer of the securities and were not acquired and are not held in connection
with or as a participant in any transaction having that purpose or effect.
<PAGE>



         After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.

February 14, 2000
- --------------------------------------------
Date

/s/ Robert P. Ruscher
- --------------------------------------------
Robert P. Ruscher


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission